

REMARKS**Interview**

Applicants and their undersigned representative thank Examiner Hines for the helpful and courteous interviews on April 12, 2007, and a follow-up interview on April 16, 2007. The submission of a terminal disclaimer was discussed during the interview. In addition, it was agreed that withdrawn claims 107-116 would be canceled by an Examiner's amendment.

Applicants thank the Examiner for withdrawing the rejection of claims 98-99 and 101-106 under 35 U.S.C. § 102; the rejection of claims 119 and 120 under 35 U.S.C. § 112, first paragraph; and the rejection of claim 117 under 35 U.S.C. § 112, second paragraph.

Double Patenting

The Advisory Action states that the rejection of claims 98-110 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 11-13 and 15-18 of U.S. Patent No. 6,136,610 will be maintained until a terminal disclaimer is filed. Applicants respectfully submit that a terminal disclaimer was submitted on April 12, 2007, in accordance with 37 CFR §1.321(c), disclaiming the terminal part of any patent granted on the present application which would extend beyond the last day of the full statutory term of U.S. Patent No. 6,136,610. The terminal disclaimer was signed on behalf of Relia Diagnostic System, LLC, the common owner of 100 percent interest in the instant application and U.S. Patent No. 6,136,610. Accordingly, Applicants respectfully request that the double patenting rejection be withdrawn.

CONCLUSION

In light of the above remarks, Applicants respectfully submit that claims 98-99, 101-106 and 117-121 satisfy all the criteria for patentability and are in condition for allowance. Applicants request that the Examiner reconsider this application with a view towards allowance and solicit an early passage of claims 98-99, 101-106 and 117-121 to issuance. The Examiner is invited to call the undersigned attorney, if a telephone call could help resolve any remaining items.


Pursuant to 37 CFR § 1.136(a)(3), the Commissioner is hereby authorized to charge all required fees, including fees under 37 CFR § 1.17 and all required extension of time fees, or credit any overpayment, to Deposit Account No. 50-1283.

Dated: April 16, 2007

Respectfully submitted,

COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
1200 19th Street N.W.; Suite 500
Washington, DC 20036-2412
Tel: (415) 693-2002
Fax: (415) 692-2222

By:


Suman R. Mirmira
Reg. No. 55,458